Skip to main content
Michael Davidson, MD, Cardiology, Chicago, IL

MichaelDavidsonMD

Cardiology Chicago, IL

Preventive Cardiology

Clinical Professor of Medicine, University of Chicago Medicine

Dr. Davidson is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Davidson's full profile

Already have an account?

  • Office

    5841 S Maryland Ave
    Chicago, IL 60637
    Phone+1 888-824-0200
    Fax+1 773-834-7300

Education & Training

  • Rush University Medical Center
    Rush University Medical CenterFellowship, Cardiovascular Disease, 1984 - 1986
  • Rush University Medical Center
    Rush University Medical CenterResidency, Internal Medicine, 1981 - 1984
  • Ohio State University College of Medicine
    Ohio State University College of MedicineClass of 1981

Certifications & Licensure

  • IL State Medical License
    IL State Medical License 1981 - 2026
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Cardiovascular Disease

Awards, Honors, & Recognition

  • CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
  • Super Doctor SuperDoctors.com
  • Fellow (FACC) American College of Cardiology

Publications & Presentations

PubMed

Lectures

  • The Power of Prevention: Lipid-Lowering Strategies for Cardiovascular Risk Reduction 
    2019 ACC Scientific Session & Expo, New Orleans - 3/17/2019
  • Lower TogetherLDL-C, Risk, Hassle, Cost 
    2019 ACC Scientific Session & Expo, New Orleans - 3/16/2019
  • How to Build a Successful Lipid Clinic 
    2019 ACC Scientific Session & Expo, New Orleans - 3/16/2019

Press Mentions

  • Novel Targets, Gene Edits, and Vaccines: Is a ‘Golden Era’ Dawning for ASCVD?
    Novel Targets, Gene Edits, and Vaccines: Is a ‘Golden Era’ Dawning for ASCVD?August 15th, 2022
  • Uptake Uncertain for Potent New LDL-Lowerer Inclisiran
    Uptake Uncertain for Potent New LDL-Lowerer InclisiranJanuary 26th, 2022
  • NewAmsterdam Pharma Announces ROSE Phase 2 Trial Results Accepted for Featured Science Presentation at 2021 AHA Scientific Sessions
    NewAmsterdam Pharma Announces ROSE Phase 2 Trial Results Accepted for Featured Science Presentation at 2021 AHA Scientific SessionsNovember 8th, 2021
  • Join now to see all

Committees

  • member, AACE/ACE COMPREHENSIVE DIABETES MANAGEMENT ALGORITHM 2015

Professional Memberships